{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T15:22:07Z","timestamp":1763738527439,"version":"3.45.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.rmed.2025.108443","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T23:28:51Z","timestamp":1760743731000},"page":"108443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The PREDMETH study of pulmonary sarcoidosis: Why did it take so long?"],"prefix":"10.1016","volume":"249","author":[{"given":"Marc A.","family":"Judson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.rmed.2025.108443_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2025.108443_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MAJ.0b013e3181b97635","article-title":"Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations","volume":"339","author":"McKinzie","year":"2010","journal-title":"Am. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.rmed.2025.108443_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.rdc.2015.08.012","article-title":"Corticosteroids in sarcoidosis","volume":"42","author":"Judson","year":"2016","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.rmed.2025.108443_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2017.09.003","article-title":"Toxicity risk from glucocorticoids in sarcoidosis patients","volume":"132","author":"Khan","year":"2017","journal-title":"Respir. Med."},{"issue":"7","key":"10.1016\/j.rmed.2025.108443_bib5","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects","volume":"68","author":"Huscher","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.rmed.2025.108443_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003432","article-title":"Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study","volume":"17","author":"Pujades-Rodriguez","year":"2020","journal-title":"PLoS Med."},{"issue":"5","key":"10.1016\/j.rmed.2025.108443_bib7","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.rmed.2009.12.009","article-title":"Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study","volume":"104","author":"Schutt","year":"2010","journal-title":"Respir. Med."},{"issue":"3","key":"10.1016\/j.rmed.2025.108443_bib8","first-page":"17859","article-title":"WASOG clinical trial endpoint task force: executive summary","volume":"42","author":"Baughman","year":"2025","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"3","key":"10.1016\/j.rmed.2025.108443_bib9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa2501443","article-title":"First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate","volume":"393","author":"Kahlmann","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.rmed.2025.108443_bib10","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.chest.2020.12.027","article-title":"Phase II investigation of the efficacy of antimycobacterial therapy in chronic pulmonary sarcoidosis","volume":"159","author":"Drake","year":"2021","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.rmed.2025.108443_bib11","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1183\/09031936.00000914","article-title":"Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis","volume":"44","author":"Judson","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.108443_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103247","article-title":"The immunopathogenesis of sarcoidosis","volume":"149","author":"Miedema","year":"2024","journal-title":"J. Autoimmun."},{"issue":"4","key":"10.1016\/j.rmed.2025.108443_bib13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1165\/rcmb.2016-0321OC","article-title":"A novel in vitro human granuloma model of sarcoidosis and latent tuberculosis infection","volume":"57","author":"Crouser","year":"2017","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"7","key":"10.1016\/j.rmed.2025.108443_bib14","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108443_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.7326\/0003-4819-135-1-200107030-00010","article-title":"Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy","volume":"135","author":"Yee","year":"2001","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108443_bib16","first-page":"70","article-title":"Infliximab for refractory sarcoidosis","volume":"18","author":"Baughman","year":"2001","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"3","key":"10.1016\/j.rmed.2025.108443_bib17","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1378\/chest.127.3.1064","article-title":"Treatment of sarcoidosis with infliximab","volume":"127","author":"Doty","year":"2005","journal-title":"Chest"},{"issue":"26","key":"10.1016\/j.rmed.2025.108443_bib18","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis","volume":"379","author":"Damsky","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.108443_bib19","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/archdermatol.2011.301","article-title":"Efficacy and safety of apremilast in chronic cutaneous sarcoidosis","volume":"148","author":"Baughman","year":"2012","journal-title":"Arch. Dermatol."},{"issue":"3","key":"10.1016\/j.rmed.2025.108443_bib20","article-title":"Roflumilast (Daliresp\u00ae) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial","volume":"38","author":"Baughman","year":"2021","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"2","key":"10.1016\/j.rmed.2025.108443_bib21","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/S2665-9913(23)00302-8","article-title":"Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial","volume":"6","author":"Redl","year":"2024","journal-title":"Lancet Rheumatol."},{"issue":"3","key":"10.1016\/j.rmed.2025.108443_bib22","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00198-2023","article-title":"High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial)","volume":"62","author":"Dhooria","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2025.108443_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00408-024-00761-8","article-title":"A snapshot of United States sarcoidosis patients and their perceived disease impact: results of the sarcoidosis research institute survey","volume":"203","author":"Obi","year":"2025","journal-title":"Lung"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125005062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125005062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T14:41:13Z","timestamp":1763736073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611125005062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":23,"alternative-id":["S0954611125005062"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108443","relation":{},"ISSN":["0954-6111"],"issn-type":[{"type":"print","value":"0954-6111"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The PREDMETH study of pulmonary sarcoidosis: Why did it take so long?","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108443","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108443"}}